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Novel Agents in the Treatment of Lung Cancer:
Fifth Cambridge Conference Assessing Opportunities
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The promise of effective targeted therapy for lung cancer requires
rigorous identification of potential targets combined with intensive
discovery and development efforts aimed at developing effective
“drugs” for these targets. We now recognize that getting the right
drug to the right target in the right patient is more complicated than
one could have imagined a decade ago. As knowledge of targets and
development of agents have proliferated and advanced, so too have
data demonstrating the biologic heterogeneity of tumors. The finding
that lung cancers are genetically diverse and can exhibit several
pathways of resistance in response to targeted agents makes the
prospect for curative therapy more daunting. It is becoming increas-
ingly clear that single-agent treatment will be the exception rather
than the rule. This information raises important new questions about
the development and assessment of novel agents in lung cancer
treatment: (1) How do we identify the most important drug targets
for tumor initiation and maintenance? (2) What is the best way to
assess drug candidates that may only be relevant in a small fraction
of patients? (3) What models do we use to predict clinical response
and identify effective combinations? And (4) how do we bring
combination regimens to the clinic, particularly when the agents are
not yet approved individually and may be under development from
different companies? The Fifth Cambridge Conference on Novel
Agents in the Treatment of Lung Cancer was held in Cambridge,
Massachusetts, on October 1–2, 2007, to discuss these questions by
reviewing recent progress in the field and advancing recommenda-
tions for research and patient care. New information, conclusions,
and recommendations considered significant for the field by the
program faculty are summarized here and presented at greater length
in the individual articles and accompanying discussions that com-
prise the full conference proceedings. A CME activity based on this
summary is also available at www.informedicalcme.com/cme.
Key Words: Lung cancer, profiling, biopsies, EGFR, VEGF, novel
targets.
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Tumor heterogeneity is a hallmark of lung cancer. Lungtumors that seem to be driven by a single mutant onco-
gene, the epidermal growth factor receptor (EGFR) gene, are
more complex than previously thought, and efforts to cure
such patients may require multiple drugs that attack multiple
targets. This realization is setting the stage for new ways to
think about how to treat lung cancers, putting emphasis on
tools to assess the characteristics of individual tumors, the
pathway(s) a given tumor is using, and ultimately, the ther-
apies that are likely be most effective in blocking that tumor’s
growth and progression. As more information emerges, it is
likely we will need to reassess how we define lung cancer,
how we approach new therapies, and how we define the
optimal way to use targeted therapies that may be effective in
subsets of patients.
THE VEGF PATHWAY AS TARGET
Angiogenesis is critical to cancer growth and is clearly
validated as a target for cancer treatment. Vascular endothe-
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lial growth factor (VEGF) is a key proangiogenic factor used
by solid tumors. Antiangiogenic therapy, in particular with
antibodies that bind VEGF, has been shown to be beneficial
(in terms of both response and survival) in many patients with
epithelial cancers. Along with VEGF, platelet-derived growth
factor (PDGF) also plays a role in non-small cell lung cancer
(NSCLC) and may be an important target of antiangiogenic
agents.
Bevacizumab (Avastin), a monoclonal antibody di-
rected against VEGF, was first demonstrated to be effective
against lung cancer in Eastern Cooperative Oncology Group
E4599, a phase 3 trial that randomized patients with newly
diagnosed, nonsquamous NSCLC to receive carboplatin/pac-
litaxel with or without bevacizumab. The E4599 study dem-
onstrated significant improvements in response rate and sur-
vival with the addition of bevacizumab, although notable
toxic effects occurred. The most concerning toxicity was
hemoptysis, a side effect that is relatively unique to lung
cancer patients. Severe life-threatening hemoptysis limits the
use of this agent to nonsquamous lung cancer and to patients
without brain metastases, need for anticoagulation, or recent
cardiac issues. The role of bevacizumab in these currently
contraindicated populations is being studied in several ongo-
ing trials. Physicians need to exercise caution when prescrib-
ing bevacizumab to elderly patients because toxic effects
seem to be more common in this patient population.
Another agent that shows promise in the treatment of
lung cancer is sunitinib (Sutent), which inhibits the VEGF
and PDGF pathways and is currently approved in the United
States for the treatment of advanced renal cell carcinoma and
imatinib (Gleevec)-refractory gastrointestinal stromal tumors.
The initial studies of sunitinib incorporated rest periods
during the drug therapy because of adverse effects such as
fatigue, diarrhea, nausea, mucositis, hypertension, myelosup-
pression, and skin abnormalities. However, some investiga-
tors believe that the 2-week break may allow tumor growth
during these rest periods, so continuous dose schedules are
under review. Currently, both intermittent and continuous
dosing strategies are being evaluated in ongoing clinical
trials. Ongoing trials are integrating sunitinib with standard
chemotherapeutic regimens in advanced NSCLC and small
cell lung cancer. Conference participants felt that exploring
whether sunitinib has activity in patients previously treated
with bevacizumab was a valid approach.
Another novel agent being investigated for lung cancer
treatment is sorafenib (Nexavar). Sorafenib, a multikinase
inhibitor of VEGF receptor (VEGFR), PDGF, KIT, FLT-3,
and RET, has also been approved in the United States for the
treatment of advanced renal cell carcinoma. Currently, at
least two phase 3 studies of sorafenib for the treatment of
lung cancer are underway, with one coming to maturity in the
near future. These studies are evaluating sorafenib as a single
agent and in combination with chemotherapy or gefitinib
(Iressa) for the treatment of refractory NSCLC. Many in the
group felt that sorafenib derived much of its clinical activity
from its anti-VEGF properties. Active Raf kinase inhibitors
are under development for RAF-mutated and RAS-mutated
lung cancer.
Vandetanib (Zactima, ZD6474) is an inhibitor of both
VEGFR and EGFR. The relative potency of this drug is
greater for VEGF but it may derive some of this unique
activity from its anti-EGFR action. This drug has been shown
to prolong disease-free survival in randomized phase 2 stud-
ies both as single agent and in combination with docetaxel in
previously-treated patients with NSCLC. In addition, vandet-
anib was evaluated alone and in combination with carbopla-
tin/paclitaxel in previously untreated lung cancer patients. In
the first-line trials, no significant survival differences were
found in the chemotherapy alone and the chemotherapy-
vandetanib arms (the vandetanib-alone arm was terminated
prematurely because of a low progression-free survival rate).
Maintenance vandetanib in responding patients with small
cell lung did not result in prolonged survival compared with
treatment with placebo. This agent is of great interest and
conference participants felt that this was an example of an
agent whose development was more rational than many
agents. It is now in phase 3 development in previously-treated
patients based on positive progression-free survival data from
randomized phase 2 trials.
Cediranib (Recentin, AZD2171) is an oral, selective
VEGF signaling inhibitor. Cediranib is currently being inves-
tigated in a Canadian phase 2/3 trial, which randomizes
patients to carboplatin/paclitaxel with or without cediranib.
Results of these trials are not expected for another 2 to 3
years. The discussion of cediranib and vandetanib touched on
the concept of whether it will be more effective to combine
two singly targeted agents such as erlotinib (Tarceva) and
bevacizumab or use one drug with dual targets such as vandet-
anib. Many of the participants considered both the ability to
modify toxicity and to validate individual targets to favor use of
multiple agents, but this remains an open question.
ANTIANGIOGENESIS IMAGING
Traditional tumor imaging uses intravenous contrast
agents as tracers: the degree of tracer accumulation observed
in the tumor is used to both detect lesions and characterize
them. Because antiangiogenic agents are postulated to affect
blood vessel permeability, their use can confound the tradi-
tional metrics used to identify a tumor and to characterize
tumor changes. This has led to a broad interest in the
development of other methods to visualize and characterize
antiangiogenic effects in cancer patients. One new technique
that seems promising is a magnetic resonance imaging-based
method that allows estimation of microvessel caliber (diam-
eter) and may be able to visualize changes over the course of
therapy. Positron emission tomography can also be used to
measure antitumor effects such as decreases in glucose use or
decreases in proliferation, though the degree to which these
methods may be influenced by permeability changes is not
yet well understood. Magnetic resonance spectroscopy also is
another tool under development that may be useful in iden-
tifying tumor characteristics and changes in response to
therapy. These more advanced imaging techniques do not
directly interrogate angiogenesis or changes in angiogenesis
after therapy but can provide important information about
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whether the antivascular effect is associated with direct or
indirect antitumor effects.
Further development of new modalities to monitor the
direct effects of antiangiogenesis, such as distributions of
microvessel diameters, and the downstream impact of these
antiangiogenic therapeutic agents, will be valuable as efforts
continue to identify optimal treatment approaches.
THE EGFR PATHWAY AS TARGET
EGFR-targeted treatments have become more impor-
tant to the therapeutic armamentarium of NSCLC. The EGFR
TKIs gefitinib and erlotinib are associated with increased
radiographic response rates and prolonged survival. Patients
benefit when treated in the second- and third-line settings and
patients with EGFR mutations likely benefit from such ther-
apies in the first-line setting. In contrast to the studies of
EGFR TKI therapy in combination with chemotherapy, sev-
eral phase I and II trials have now shown that the monoclonal
antibody cetuximab (Erbitux) may improve response and
prolong survival when added to first-line platinum-based
chemotherapy.
Identifying which patients benefit the most from
EGFR-based therapy has been a major endeavor in the lung
cancer research community for the past 5 years. Retrospec-
tive data have indicated that increased EGFR gene copy
number detected by fluorescent in situ hybridization (FISH) is
a good predictive marker, especially in trials where TKIs are
compared with best supportive care. It seems that EGFR copy
number may also predict benefit from cetuximab therapy in
lung and colon cancers. However, the group also considered
data demonstrating that FISH does not identify patients who
benefit from gefitinib over docetaxel (Taxotere) in a subset
analysis of the recently presented INTEREST study. Clearly,
more work is needed to elucidate the role of EGFR FISH as
a biomarker for selecting patients most appropriate for EGFR
TKI therapy. The FISH assay is now being validated in
prospective clinical studies. Through the Intergroup mecha-
nism an NCI/CPATH initiated prospective study is planned to
prospectively validate primarily EGFR gene copy number by
FISH as a predictive marker for EGFR TKI therapy.
Somatic mutations in EGFR have been documented to
lead to activation of EGFR and are thought to be associated
with a dependency on EGFR signaling. These mutations are
associated with a several-fold increase in response rates to
EGFR TKIs and possibly increased survival after treatment.
The discovery of these mutations has led to exploration of
genotype-directed therapy, which aims to create a more
specific treatment algorithm based on the tumor biology of
individual patients. Internationally, several groups have con-
ducted first-line trials wherein patients with NSCLC are
selected for gefitinib or erlotinib therapy based on EGFR
mutation status. The results of these trials are promising with
response rates ranging from 55% to 80% and median pro-
gression free survivals in excess of 9 months. Conference
participants were enthusiastic about these initial studies but
agreed that randomized trials comparing first-line EGFR TKI
treatment with first-line chemotherapy were needed in this
unique population of patients, because EGFR mutations may
also be associated with a better prognosis independent of
therapy.
Most NSCLC patients with EGFR-dependent tumors,
as evidenced by mutations in EGFR, experience an initial
response to treatment with erlotinib or gefitinib. However, a
few patients with EGFR mutations are noted to have primary
resistance to these TKIs, and essentially all of the EGFR
mutation-positive patients who initially respond to TKI treat-
ment eventually acquire resistance. The T790M mutation in
EGFR has been identified in nearly half of resistant patients.
Recently, a second resistance mechanism, amplification of
C-MET has been shown to account for an additional signifi-
cant proportion of resistant patients. Several second-genera-
tion EGFR TKIs that have activity against cells harboring the
T790M mutation are currently being studied: HKI-272, a
second-generation irreversible EGFR TKI that also inhibits
HER2; XL647, a reversible inhibitor of EGFR, HER2, and
VEGFR; and BIBW2992, an irreversible EGFR TKI that also
inhibits HER2 and VEGFRs. These agents have the potential
to prevent or delay the development of acquired resistance or
overcome acquired resistance in patients previously treated
with gefitinib or erlotinib, and are worthy of study both in
patients who have not received prior erlotinib or gefitinib and
in patients with acquired resistance. C-MET inhibitors given
in conjunction with EGFR inhibition are also under study as
a means to overcome resistance.
Because mutant EGFR has been demonstrated to be a
client protein for the heat shock protein 90 (Hsp90) chaper-
one, inhibitors of HSP90 are currently being evaluated.
EGFR series harboring exon 20 insertions that are not inhib-
ited by erlotinib, as well as those with secondary T790M
mutation conferring erlotinib resistance remain dependent on
Hsp90 for conformational stability. c-Met is also an Hsp90
client. Therefore, Hsp90 inhibitors may be useful against EGFR
mutant lung cancers with primary or acquired TKI resistance.
Additionally, lung cancers expressing wild-type EGFR may
depend on other kinases that are Hsp90 clients, so that the
strategy of Hsp90 inhibition may be useful for multiple lung
cancer subsets. The geldanamycin family of compounds has
been most well-studied, including 17-AAG, 17-DMAG, and
IPI-504, which have high binding affinity to human Hsp90 and
have entered phase 1 and 2 trials. However, because of the
limitations of these geldanamycin derivatives, including off-
target toxicity and formulation challenges, other Hsp90 inhibi-
tors are also being explored, including purine scaffold inhibitors
such as CNF-2024 and diarylpyrazole compounds such as the
3,4-diarylisoxazole NVP-AUY922/VER-52296. These and other
Hsp90 inhibitors are in early phase 1 development.
The conundrum of how to treat KRAS mutant lung
cancer was discussed at length at the meeting. This is a
particularly attractive area of investigation because tumors
that harbor mutant KRAS seem to be refractory to most
available systemic chemotherapies and also do not respond to
EGFR-TKIs. Currently, no selective, specific inhibitor of the
KRAS pathway has been successfully developed for clinical
use. Although some treatment strategies targeting KRAS
have resulted in antitumor activity, it is still unclear whether
KRAS inhibition will be able to be realized as a therapeutic
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option. However, this group remains an important subset of
lung cancers that need to be addressed in future studies of novel
agents that target the pathway, such as inhibitors of MEK and
BRAF. Thus, aside from serving as a negative predictive factor
for EGFR-TKI therapy, sequencing patients’ specimens for
KRAS mutations may have value in identifying patients who
should be treated with novel agents.
OTHER TARGETS
Another novel approach to the treatment of lung
cancer is immunotherapeutic vaccines. Several vaccines
are currently being investigated in randomized trials, in-
cluding L-BLP25 (Stimuvax), BEC-2 (Mitumomab), 1E10,
PF-3512676 (Promune), melanoma-associated antigen A3
(MAGE-A3) immunotherapeutic, granulocyte-macrophage
colony-stimulating factor-transduced allogeneic cancer cellu-
lar immunotherapy (GVAX), and belagenpumatucel-L (Lu-
canix). Many of these vaccines have intriguing early data
such as prolonged disease-free survival compared with his-
torical controls. Large phase 3 trials are underway examining
the role of therapeutic vaccines in patients with lung cancer.
Conference participants considered that, as with other tar-
geted agents, it is probable that vaccines may be beneficial for
certain subgroups of patients, and so the advancement and
incorporation of correlative studies within vaccine trials will
be crucial to avoid discarding a vaccine that may have
potential benefit for some patients.
As noted earlier, the future of lung cancer treatment
will likely require combination therapy. Some of these com-
binations will include a new, targeted drug given with che-
motherapy whereas others will be combinations of targeted
drugs without any traditional chemotherapeutic agents. To
optimize treatment, it will be essential that the most active
chemotherapeutic agents are identified. Currently, platinum-
containing doublet therapy is the standard first-line treatment
of advanced NSCLC. The combinations of cisplatin and
paclitaxel (Taxol), cisplatin and gemcitabine (Gemzar), cis-
platin and docetaxel, and carboplatin and paclitaxel have
produced similar response rates and survival advantages.
Some toxicity differences may help to guide investiga-
tors in optimal strategies for adding targeted agents to estab-
lished doublets, but the relative efficacy of platinum-based
double regimens is very similar. Several newer cytotoxic
agents are in development for lung cancer. These agents
include drugs that are modifications of existing agents, such
as albumin-bound paclitaxel, and oral topotecan. Others, such
as pemetrexed (Alimta), vinflunine (Javlor), or ixabepilone
(BMS-247550), are newer-generation agents derived from
previously identified drug classes. Of these agents, pem-
etrexed, in combination with either cisplatin or carboplatin,
has shown similar activity to established platinum-based
doublets and will likely become a clinically widely used and
often studied base for combination with novel drugs. Like-
wise, albumin-bound paclitaxel (Abraxane) may provide cer-
tain advantages over existing taxanes and its evaluation as a
cytotoxic to pair with standard chemotherapy is under way.
IMPORTANCE OF MOLECULAR PROFILING,
PRECLINICAL MODELS, AND TISSUE BIOPSIES
As has been the case in prior years of this program,
participants emphasized the need for increased focus on
developing and using preclinical models in the development
of targeted agents. Murine models, including both xenografts
and genetically engineered mice, were thought by the partic-
ipants to be useful tools in assessing drug efficacy. Broad cell
line screening was also felt to be vital. The program faculty
stressed the need to use all three techniques to most effec-
tively develop drugs. There was no single technique that
provided guidance in optimizing leads in all situations. It was
emphasized that flexibility in methods to assess new candi-
date targets and newly developed drug compounds was cen-
tral to potential success.
The importance of using preclinical modeling to under-
stand the biology of drugs and targets is driven by the need
for sufficient data to support rational trial design, including
decision making for safety, dose, and endpoints. Participants
felt strongly that a dynamic assessment of genetics and
“target biology” is essential to inform the trial process. To
move toward the goal of individualizing or personalizing the
approach to lung cancer treatment, molecular profiling of
treatment-sensitive and treatment-resistant tumor molecular
subtypes at the time of diagnosis, during treatment and at
relapse, will be essential. There was agreement that clinical
trials need to mandate collection of tumor specimens at
baseline and at relapse whenever feasible. With better cor-
relative studies, even negative clinical trials can provide
insights to advance our understanding of the disease. Confer-
ence participants emphasized the need for regular and itera-
tive communication between clinicians and basic scientists.
This will ensure that preclinical studies are focused on rele-
vant clinical needs and that preclinical data appropriately
inform patient selection and other aspects of trial design.
Keeping basic scientists appraised of clinical information to
expedite efforts in biomarker and assay development was also
considered to be essential.
Conference participants noted that core biopsies will
play an increasingly important role in lung cancer diagnosis
as they do now for lymphoma. Needle aspirations do not
yield sufficient tumor material for both standard pathologic
evaluation and molecular diagnostics. Broad sequencing of
suspected lung oncogenes will have a critical role in clinical
decision making in the future. Alternative technologies, such
as assessment of circulating tumor cells and circulating serum
DNA, will be essential to increase our access to sufficient and
longitudinal tumor tissue samples.
INDIVIDUALIZING THERAPY—PATIENT
SELECTION
Recent studies have demonstrated that patients with
specific mutations in the EGFR gene or increased numbers of
gene copies had a significantly higher likelihood of respond-
ing to the EGFR TKIs gefitinib and erlotinib. These findings
have sparked widespread efforts to find ways to better match
patients with effective therapies. These efforts have included
evaluating gene mutation status, gene copy number, and
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surface protein expression and have led to the identification
of smaller groups of patients who might experience larger
degrees of benefit. Interest in this topic remains very strong as
more agents move forward that show signs of being highly
efficacious in a small percentage of patients.
Conference participants noted that although the bi-
omarkers used now are not yet mature or validated for patient
selection, it will be increasingly important to think about not
only who to select for treatment but also who not to select for
treatment in trial designs for new agents. For example, it has
recently been shown that patients with an RAS mutation have
almost no chance of responding to EFGR-TKI therapy.
Knowing this in advance of EGFR-TKI therapy is just as
important as knowing which patients have EGFR mutations
or high copy number and might respond dramatically. Many
of the faculty commented that biomarkers are likely to be just
as useful in negative patient selection (helping to decide when
an agent will be of no benefit) as in positive patient selection
(given only to those in whom benefit has been demonstrated).
Trying to find a biomarker that will predict a positive out-
come when the outcome is on a continuum, from a small
improvement in survival to a dramatic improvement in sur-
vival, is challenging but important.
CLINICAL TRIAL DESIGN—MEETING THE
CHALLENGES OF COMBINATION THERAPIES
Conference participants were uniform in their assess-
ment that a disease as complicated as NSCLC will likely not
be cured, or even effectively controlled, with monotherapy.
Combinations of targeted agents and of targeted agents with
chemotherapy are essential. Conference faculty noted that
experience in combination trials over the past decade has
been very disappointing. With the notable exception of trials
combining chemotherapy with cetuximab and chemotherapy
with bevacizumab, most studies have failed to demonstrate
that adding a targeted drug to standard combination chemother-
apy is able to improve outcome. The results of combinations of
targeted agents are even more rudimentary at this point.
Several participants noted that contributing factors to
the low level of success in combination trials include a lack
of preclinical models that faithfully represent human disease
and the economic climate of drug development, which forces
phase 3 trial design before adequate phase 2 work has been
completed. Most of the failed studies were preceded by a
single-arm phase 2 study or only phase 1 study. For future
studies of novel agents and combination studies including
novel agents, conference participants strongly recommended
that the process should start with a thorough and critical
assessment of preclinical data followed by adequate phase 2
studies, preferably in molecularly defined populations se-
lected on the basis of a demonstrated mechanism of action.
Of course, it was recognized that this is unlikely until we
better understand tumor and patient heterogeneity. Partici-
pants strongly recommended that investigators should make
every effort to mandate tissue and serum studies as part of
every new trial of a targeted agent. Performing correlative
studies at all phases of clinical development may provide
valuable insights into the mechanisms of sensitivity and
resistance.
It was strongly recommended that positive, randomized
phase 2 studies be completed and assessed as positive before
proceeding to phase 3 trials. If the earlier studies are negative
or questionable, this is the time to rethink the hypothesis or
perform the study in a different way. This is a challenge to
both the academic community and industry to step back and
do things more prudently. Looking forward to the large
number of new agents in development, the need to establish
both a rational procedure for selecting combinations for
further study and appropriate approaches to patient selection
is clear.
COOPERATIVE GROUP STUDIES
A discussion of cooperative group trials in developing
targeted agents for lung cancer highlighted strong feelings
that the system is important but also is facing issues in
administration, delays, funding, and accessibility. There was
broad agreement among the conference faculty that the co-
operative group system has made significant contributions
and in most cases led the effort for most of the advances in
lung cancer therapy for the past decade. It was agreed that the
cooperative groups provide a unique opportunity to conduct
important trials that do not have an obvious commercial
angle. Most felt that cooperative group trials allow broader
access to trial design and implementation than industry-
supported trials. They also allow data pooling across studies
and provide valuable opportunities for young investigators to
access training, mentoring, and data. However, concern was
expressed that almost all of the “significant” recent cooper-
ative group studies are phase 3 studies and that the system
generally adds 1 to 3 years to study implementation. Today it
is widely considered to be extremely time consuming and
inefficient to put a phase 2 study through the cooperative
group system. If trends that require more comprehensive data
acquisition for drug approval studies continue, many ques-
tioned the fiscal viability of the cooperative groups. The
limited payments for patients in the studies are raising finan-
cial issues for academic centers. If these issues are not
addressed, fewer innovative studies will be able to use this
framework. Conference participants were united in their be-
lief that the cooperative group system needs to be saved but
were unsure how best to do this.
CONCLUSION
The 2007 Cambridge Conference concluded with par-
ticipants expressing hope that continued work in understand-
ing lung cancer biology will drive new therapeutic develop-
ments. Participants were unanimous in stressing that
investigators need to be committed to trials that gather tissue
to determine if target pathways are being affected by a given
therapy. This collection of tissue is important in determining
the potential impact of treatments in overcoming resistance.
Despite the hurdles experienced over the past 5 years in
targeted drug development, participants felt that major ac-
complishments have been made. The discovery of EGFR
mutations and their potential role in the biology of EGFR-
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driven cancers is one notable achievement, as is the discovery
that the targeted agent bevacizumab is able to improve
survival when added to standard chemotherapy. Over the next
5 years we hope to identify agents that have activity in the
treatment of tumors that are resistant to first-generation
EGFR inhibitors and develop oral VEGF inhibitors that have
activity in lung cancer. In the meantime, we should also
recognize that this field has made rapid progress over the past
decade. Our understanding of the underlying biology of
disease has expanded tremendously, as has recognition of its
complexity; a variety of important lung cancer targets have
been identified and characterized; and several important new,
targeted therapies are now part of our treatment armamen-
tarium. This new information and these new tools are
radically changing how we think about lung cancer, how
we treat patients, and how we need to approach future drug
development.
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